{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:00:28Z","timestamp":1790834428686,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070967"],"award-info":[{"award-number":["82070967"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770930"],"award-info":[{"award-number":["81770930"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201189"],"award-info":[{"award-number":["82201189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Department of Science and Technology of Hunan Province","doi-asserted-by":"publisher","award":["No. 2023SK2029"],"award-info":[{"award-number":["No. 2023SK2029"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020795","name":"Outstanding Youth Scientist Foundation of Hunan Province","doi-asserted-by":"publisher","award":["No. 2025JJ20080"],"award-info":[{"award-number":["No. 2025JJ20080"]}],"id":[{"id":"10.13039\/501100020795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>Systematic review and Bayesian network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of methylprednisolone (MP), erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), and minocycline for the treatment of acute spinal cord injury (ASCI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      MEDLINE, Embase, the Cochrane Library, and\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      were searched from inception to 15 June 2025. Randomized and nonrandomized comparative studies were eligible. Bayesian random-effects network meta-analyses compared MP, EPO, EPO plus MP, G-CSF, and minocycline. Treatment effects were reported as odds ratios (ORs) or mean differences (MDs) with 95% credible intervals (CrIs). Model convergence and fit, heterogeneity, predictive intervals, and global and local inconsistency were evaluated. Follow-up-stratified and exploratory restriction analyses were performed where feasible. Formal comparison-level Confidence in Network Meta-Analysis (CINeMA) assessment was not feasible; certainty was appraised qualitatively across its six domains.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty comparative reports were included: nine randomized and 11 nonrandomized reports. For neurological grade improvement, G-CSF was associated with higher odds of improvement than the common control node (OR = 5.12, 95% CrI 1.15\u201332.42). Estimates for EPO (OR = 4.87, 95% CrI 0.44\u2013135.90), EPO plus MP (OR = 3.44, 95% CrI 0.09\u2013164.02), and MP (OR = 1.31, 95% CrI 0.30\u20135.72) were imprecise and included the null. For change in ASIA Motor Score, G-CSF had the largest point estimate (MD = 11.49, 95% CrI \u22120.44 to 23.49), followed by minocycline (MD = 6.83, \u221215.24\u201328.75), EPO (MD = 6.75, \u221213.16\u201326.42), and MP (MD = 2.28, \u22126.24\u201310.94); all credible intervals crossed zero. For overall adverse events, the estimate for MP was imprecise (OR = 1.13, 95% CrI 0.58\u20132.34), while the G-CSF effect was not reliably estimable because near-complete event occurrence produced a highly prior-sensitive posterior. Other safety estimates were imprecise.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>G-CSF showed a potential beneficial signal for neurological grade improvement. However, the limited evidence base, inclusion of nonrandomized and nonconcurrent comparisons, substantial heterogeneity, wide credible and predictive intervals, and uncertain transitivity preclude definitive conclusions about comparative efficacy or safety. Treatment rankings should be regarded as exploratory and do not establish the superiority of any intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/<\/jats:ext-link>\n                      , identifier CRD420251027856.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1942918","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:41:20Z","timestamp":1790833280000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of four immunomodulatory agents for acute spinal cord injury: a systematic review and Bayesian network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yue","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The Second Xiangya Hospital, Central South University","place":["Changsha, China"]},{"name":"Hunan Clinical Research Center of Ophthalmic Disease","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghan","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Xiangya Hospital, Central South University","place":["Changsha, China"]},{"name":"Hunan Clinical Research Center of Ophthalmic Disease","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuerong","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Xiangya Hospital, Central South University","place":["Changsha, China"]},{"name":"Hunan Clinical Research Center of Ophthalmic Disease","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Xiangya Hospital, Central South University","place":["Changsha, China"]},{"name":"Hunan Clinical Research Center of Ophthalmic Disease","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Xiangya Hospital, Central South University","place":["Changsha, China"]},{"name":"Hunan Clinical Research Center of Ophthalmic Disease","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Xiangya Hospital, Central South University","place":["Changsha, China"]},{"name":"Hunan Clinical Research Center of Ophthalmic Disease","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17018","DOI":"10.1038\/nrdp.2017.18","article-title":"Traumatic spinal cord injury","volume":"3","author":"Ahuja","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B2","first-page":"275","article-title":"Erythropoietin plus methylprednisolone or methylprednisolone in the treatment of acute spinal cord injury: a preliminary report","volume":"52","author":"Alibai","year":"2014","journal-title":"Acta Med. Iran."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1089\/neu.2014.3429","article-title":"Modulating inflammatory cell responses to spinal cord injury: all in good time","volume":"31","author":"Bowes","year":"2014","journal-title":"J. Neurotrauma"},{"key":"B4","doi-asserted-by":"publisher","first-page":"CD001046","DOI":"10.1002\/14651858.CD001046.pub2","article-title":"Steroids for acute spinal cord injury","volume":"1","author":"Bracken","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3171\/jns.1992.76.1.0023","article-title":"Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second national acute spinal cord injury study","volume":"76","author":"Bracken","year":"1992","journal-title":"J. Neurosurg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/brain\/aws072","article-title":"Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury","volume":"135","author":"Casha","year":"2012","journal-title":"Brain"},{"key":"B7","first-page":"22267","article-title":"The effect of erythropoietin in the treatment of acute spinal cord injury","volume":"9","author":"Cheng","year":"2016","journal-title":"Int. J. Clin. Exp. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s10072-015-2182-5","article-title":"Tolerability and efficacy of erythropoietin treatment in traumatic spinal cord injury: a preliminary randomized comparative trial versus methylprednisolone","volume":"36","author":"Dalla Costa","year":"2015","journal-title":"Neurol. Sci."},{"key":"B9","article-title":"Chapter 10: analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s13311-018-0632-5","article-title":"Clinical trials in traumatic spinal cord injury","volume":"15","author":"Donovan","year":"2018","journal-title":"Neurotherapeutics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1089\/neu.2015.3963","article-title":"Methylprednisolone for the treatment of patients with acute spinal cord injuries: a propensity score-matched cohort study from a Canadian multi-center spinal cord injury registry","volume":"32","author":"Evaniew","year":"2015","journal-title":"J. Neurotrauma"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1002\/sim.9562","article-title":"Network meta-analysis of rare events using penalized likelihood regression","volume":"41","author":"Evrenoglou","year":"2022","journal-title":"Stat. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1089\/neu.2023.0163","article-title":"Safety and efficacy of riluzole in acute spinal cord injury study (RISCIS): a multi-center, randomized, placebo-controlled, double-blinded trial","volume":"40","author":"Fehlings","year":"2023","journal-title":"J. Neurotrauma"},{"key":"B14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41393-020-00604-2","article-title":"The effect of combination therapy with erythropoietin and methylprednisolone in patients with traumatic cervical spinal cord injury: a pilot randomized controlled trial","volume":"59","author":"Ganjeifar","year":"2021","journal-title":"Spinal Cord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/sc.1995.71","article-title":"Utilization and effectiveness of methylprednisolone in a population-based sample of persons with spinal cord injury","volume":"33","author":"Gerhart","year":"1995","journal-title":"Paraplegia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/00005373-199702000-00017","article-title":"Consequences of high-dose steroid therapy for acute spinal cord injury","volume":"42","author":"Gerndt","year":"1997","journal-title":"J. Trauma"},{"key":"B17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12974-021-02337-2","article-title":"Inflammation after spinal cord injury: a review of the critical timeline of signaling cues and cellular infiltration","volume":"18","author":"Hellenbrand","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-023-01477-6","article-title":"Spinal cord injury: molecular mechanisms and therapeutic interventions","volume":"8","author":"Hu","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.2174\/1570159X23666250313104646","article-title":"Exploring the effectiveness and potential pharmacological mechanism of minocycline for spinal cord injury through meta-analysis and network pharmacology","volume":"23","author":"Hu","year":"2025","journal-title":"Curr. Neuropharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/BRS.0000000000000121","article-title":"Multicenter prospective nonrandomized controlled clinical trial to prove neurotherapeutic effects of granulocyte colony-stimulating factor for acute spinal cord injury: analyses of Follow-up cases after at least 1 year","volume":"39","author":"Inada","year":"2014","journal-title":"Spine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/BRS.0b013e3181b613c7","article-title":"Does high-dose methylprednisolone sodium succinate really improve neurological status in patients with acute cervical cord injury? A prospective study of neurological recovery and early complications","volume":"34","author":"Ito","year":"2009","journal-title":"Spine (Phila Pa 1976)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jconrel.2015.08.060","article-title":"Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injury","volume":"219","author":"Kabu","year":"2015","journal-title":"J. Control Release"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e50391","DOI":"10.1371\/journal.pone.0050391","article-title":"Granulocyte colony-stimulating factor (G-CSF) protects oligodendrocyte and promotes hindlimb functional recovery after spinal cord injury in rats","volume":"7","author":"Kadota","year":"2012","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00586-014-3373-0","article-title":"Neuroprotective therapy with granulocyte colony-stimulating factor in acute spinal cord injury: a comparison with high-dose methylprednisolone as a historical control","volume":"24","author":"Kamiya","year":"2015","journal-title":"Eur. Spine J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3171\/2011.5.SPINE10421","article-title":"Neuroprotective effects of granulocyte colony-stimulating factor and relationship to promotion of angiogenesis after spinal cord injury in rats: laboratory investigation","volume":"15","author":"Kawabe","year":"2011","journal-title":"J. Neurosurg. Spine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"13435","DOI":"10.1523\/JNEUROSCI.3257-09.2009","article-title":"Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord","volume":"29","author":"Kigerl","year":"2009","journal-title":"J. Neurosci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/brain\/awaa466","article-title":"Randomized trial of granulocyte colony-stimulating factor for spinal cord injury","volume":"144","author":"Koda","year":"2021","journal-title":"Brain"},{"key":"B29","doi-asserted-by":"publisher","first-page":"187S","DOI":"10.1177\/21925682231202348","article-title":"A clinical practice guideline for the management of patients with acute spinal cord injury: recommendations on hemodynamic management","volume":"14","author":"Kwon","year":"2024","journal-title":"Glob. Spine J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1212\/WNL.0000000000007998","article-title":"High-dose methylprednisolone for acute traumatic spinal cord injury: a meta-analysis","volume":"93","author":"Liu","year":"2019","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"102598","DOI":"10.1016\/j.arr.2024.102598","article-title":"Global, regional, and national burden of spinal cord injury from 1990 to 2021 and projections for 2050: a systematic analysis for the global burden of disease 2021 study","volume":"103","author":"Lu","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s00586-008-0829-0","article-title":"Erythropoietin in spinal cord injury","volume":"18","author":"Matis","year":"2009","journal-title":"Eur. Spine J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/00007632-200102150-00020","article-title":"Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury","volume":"26","author":"Matsumoto","year":"2001","journal-title":"Spine (Phila Pa 1976)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/14737175.2025.2470326","article-title":"Therapeutic strategies that modulate the acute phase of secondary spinal cord injury scarring and inflammation and improve injury outcomes","volume":"25","author":"Migliorini","year":"2025","journal-title":"Expert Rev. Neurother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1186\/s40001-026-04005-8","article-title":"Pharmacotherapy in the acute phase of secondary spinal cord injury: an updated narrative review","volume":"31","author":"Migliorini","year":"2026","journal-title":"Eur. J. Med. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jor.2024.11.025","article-title":"Effect of granulocyte colony-stimulating factor (G-CSF) in functional outcome of acute spinal cord injury patients: a single-blinded randomized controlled trial","volume":"64","author":"Mounissamy","year":"2025","journal-title":"J. Orthop."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/sj.sc.3100962","article-title":"Pharmacological therapy of spinal cord injury during the acute phase","volume":"38","author":"Pointillart","year":"2000","journal-title":"Spinal Cord."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/s1474-4422(23)00287-9","article-title":"Global, regional, and national burden of spinal cord injury, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"22","author":"Safdarian","year":"2023","journal-title":"Lancet Neurology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s10143-024-02372-6","article-title":"An updated systematic review of neuroprotective agents in the treatment of spinal cord injury","volume":"47","author":"Serag","year":"2024","journal-title":"Neurosurg. Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41586-018-0068-4","article-title":"Dissecting spinal cord regeneration","volume":"557","author":"Sofroniew","year":"2018","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B43","volume-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019"},{"key":"B44","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.injury.2007.12.005","article-title":"Early complications of high-dose methylprednisolone in acute spinal cord injury patients","volume":"39","author":"Suberviola","year":"2008","journal-title":"Injury"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1213\/ANE.0000000000001906","article-title":"Methylprednisolone therapy in acute traumatic spinal cord injury: analysis of a regional spinal cord model systems database","volume":"124","author":"Sunshine","year":"2017","journal-title":"Anesth. Analg."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1007\/s00586-012-2213-3","article-title":"Neuroprotective therapy using granulocyte colony-stimulating factor for acute spinal cord injury: a phase I\/IIa clinical trial","volume":"21","author":"Takahashi","year":"2012","journal-title":"Eur. Spine J."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1097\/01.brs.0000250273.28483.5c","article-title":"Effects of the second national acute spinal cord injury study of high-dose methylprednisolone therapy on acute cervical spinal cord injury: results in spinal injuries center","volume":"31","author":"Tsutsumi","year":"2006","journal-title":"Spine (Phila Pa 1976)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1089\/neur.2023.0114","article-title":"Safety and efficacy of riluzole in traumatic spinal cord injury: a systematic review with meta-analyses","volume":"5","author":"Weisbrod","year":"","journal-title":"Neurotrauma Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1089\/neur.2023.0099","article-title":"Granulocyte-colony stimulating factor improves neurological and functional outcomes in patients with traumatic incomplete spinal cord injuries: a systematic review with meta-analyses","volume":"5","author":"Weisbrod","year":"","journal-title":"Neurotrauma Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/brain\/awg178","article-title":"Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice","volume":"126","author":"Wells","year":"2003","journal-title":"Brain"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1942918\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:41:23Z","timestamp":1790833283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1942918\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":50,"alternative-id":["10.3389\/fphar.2026.1942918"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1942918","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1942918"}}